cslbehring.es
Provided by Alexa ranking, cslbehring.es has ranked N/A in N/A and 2804582nd on the world. It is hoted in N/A with IP address 12.3.33.229. The home page has 0 external link.
Top keyword related from Search Engine of cslbehring.es
Traffic Ranks of cslbehring.es
Owner: |
N/A |
RANK: |
2804582 |
Country code: |
N/A |
Country name: |
N/A |
Rank on country: |
N/A |
Host: |
N/A |
Ip: |
12.3.33.229 |
Ref link: |
|
Extension: |
es |
-
1. Global Biotechnology Company | CSL
Link: https://www.csl.com/we-are-csl/our-businesses-and-products/csl-behring
Description: Web ResultCSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and …
-
2. Global Biotechnology Company | CSL
Link: https://www.csl.com/
Description: Web ResultCSL Behring. Leading the Way in Treating Rare and Serious Diseases. CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
-
3. CSL Behring - Wikipedia
Link: https://en.wikipedia.org/wiki/CSL_Behring
Description: Web ResultCSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. The company is a combination of Behringwerke, founded in 1904 in Marburg , Germany by Emil von Behring , and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to …
-
4. We Are CSL | CSL
Link: https://www.csl.com/we-are-csl
Description: Web ResultCSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and …
-
5. Our Company - CSL Behring
Link: https://www.cslbehring.ch/en-us/our-company
Description: Web ResultMore than 100 years ago, CSL was formed to save lives using the latest technologies. In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in …
-
6. Our Company - CSL Behring
Link: https://www.cslbehring.de/en-us/our-company
Description: Web ResultWhat Drives Us. Commitment to the well-being of our patients – that’s what we stand for at CSL Behring Marburg. As a global biotechnology company and major employer in Middle Hesse, we work every day for our patients around the world and do so with smiles on our faces. Learn More.
-
7. Products - CSL Behring
Link: https://www.cslbehring.ch/en-us/products
Description: Web ResultProducts. CSL Behring Switzerland. Products. Our Products. We specialise in the manufacture of biotherapeutic products, with more than a century of experience in the treatment of various diseases worldwide. In contrast to chemically manufactured pharmaceuticals, biotherapeutic products are manufactured from human plasma …
-
8. Global Newsroom | CSL
Link: https://newsroom.csl.com/
Description: Web ResultFeb 12, 2024 - Strong CSL Behring portfolio growth especially Ig FINANCIAL HIGHLIGHTS4 Revenue $8.05 billion, up 11% at CC3 NPAT $1.90 billion1, up 17% NPAT $1.94 billion1 at CC3, up 20% NPATA $2.02 billion1,2 ,... Read more news from CSL. CSL Behring.
-
9. CSL Behring Announces the First Patient Has Received FDA …
Link: https://newsroom.csl.com/2023-06-20-CSL-Behring-Announces-the-First-Patient-Has-Received-FDA-Approved-HEMGENIX-R-etranacogene-dezaparvovec-drlb-for-Hemophilia-B
Description: Web ResultKING OF PRUSSIA, Pa., June 20, 2023 / PRNewswire / -- Global biotechnology leader CSL Behring today announced that the first patient has received U.S. Food and Drug Administration (FDA) approved HEMGENIX ® (etranacogene dezaparvovec-drlb) for hemophilia B in the United States.
-
10. Our Story - CSL Behring
Link: https://www.cslbehring.ch/en-us/our-company/our-story
Description: Web ResultOur Story. CSL Behring Switzerland. Our Company. Our Story. CSL Behring – a specialist in biotherapeutics for more than 100 years. Our 100th anniversary video tells you everything you need to know about our promise to our patients. 2021 Operating licence and start of production at CSL Behring Lengnau AG.